HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64
9/22/2026
Impact: 80
Healthcare
HC Wainwright & Co. analyst Joseph Pantginis has maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX) and increased the price target from $42 to $64.
AI summary, not financial advice
Share: